文献速递胸部肿瘤放疗姑息放疗与转移瘤

根治性半胸放疗对比姑息放疗治疗非转移性恶性胸膜间皮瘤:3期随机临床试验结果

Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-11-28

这项3期随机试验将108例接受非根治性保肺手术和化疗的非转移性恶性胸膜间皮瘤患者按1:1随机分配至根治性半胸放疗(RHR)或姑息放疗(PR)。RHR显著改善生存,但毒性不可忽视。

要点

  • RHR组11例急性≥3级毒性,17例3-4级晚期毒性,9例≥2级肺炎(含1例5级)。
  • RHR总剂量50 Gy/25次,大体残留病灶同步整合加量至60 Gy。

核心结论

  • 与姑息治疗相比,RHR显著改善接受非根治性保肺手术和化疗的MPM患者生存。
  • RHR伴随不可忽视的毒性反应。

研究设计与样本

  • 3期随机临床试验,2014年8月至2018年5月纳入108例组织学诊断的非转移性MPM患者。
  • 患者接受非根治性保肺手术和化疗后按1:1随机分配至RHR组(55例)或PR组(53例)。
  • 主要终点为OS,次要终点包括局部控制、无远处转移生存、无进展生存及急性和晚期毒性率。

主要发现

  • RHR组11例发生≥3级急性毒性,17例发生3-4级晚期毒性。
  • RHR组9例发生≥2级肺炎,其中1例为5级。

关键数值与推荐

  • RHR涉及胸膜腔总剂量50 Gy/25次,大体残留病灶同步整合加量至60 Gy。
  • 样本量108例基于α=0.05、统计功效80%计算,以证明RHR可改善2年OS。

临床怎么用

  • 对接受非根治性保肺手术和化疗的非转移性MPM患者,可考虑RHR以改善生存。
  • 实施RHR需权衡其不可忽视的急性和晚期毒性风险。

局限性

  • 中位随访仅14.6个月。
  • 毒性谱不可忽视,包括1例5级肺炎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We conducted a phase 3 randomized clinical trial to assess whether radical hemithoracic radiation therapy (RHR) compared with palliative radiation therapy (PR) can achieve overall survival (OS) advantages in patients with malignant pleural mesothelioma (MPM). METHODS AND MATERIALS: From August 2014 to May 2018, patients with histologically diagnosed nonmetastatic MPM, who underwent nonradical lung-sparing surgery and chemotherapy (CHT), were randomly assigned (1:1) to receive RHR or PR. RHR total dose to the involved pleural cavity was 50 Gy in 25 fractions, and the gross residual disease received a simultaneous integrated boost of 60 Gy. The primary endpoint was OS. Secondary endpoints were local control, distant metastasis-free survival, progression-free survival, and acute and late toxicity rates. A sample size of 108 patients considering a type I error (α) of 0.05 and a statistical power of 80% was calculated to prove that RHR could improve the 2-year OS. OS was estimated with the Kaplan-Meier method and the log-rank test (2-sided) tested differences between arms. The univariate and multivariate analyses were performed using Cox proportional hazard model. Possible prognostic factors investigated: age, sex, performance status, lung surgery, gross residual disease, and histology. RESULTS: One hundred eight patients were randomized: 53 to the PR arm and 55 to the RHR arm. Median follow-up was 14.6 months. The 2-year OS rate was 58% in the RHR arm versus 28% in the PR arm (hazard ratio, 0.54; 95% confidence interval, 0.31-0.95; P = .031). In the RHR arm: 11 patients experienced acute toxicity grade ≥3, 17 patients had grade 3 to 4 late toxicity. Nine patients experience a grade ≥2 pneumonitis, including 1 patient with grade 5. CONCLUSIONS: RHR significantly improves survival in patients with MPM treated with nonradical lung-sparing surgery and CHT compared with palliative treatments, although it is associated with a nonnegligible toxicity profile.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Trovo M, Relevant A, Polesel J, et al. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 33259933. doi:10.1016/j.ijrobp.2020.11.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。